Doctors for Lung cancer in the Southern suburbs of Athens

Dr. Kokkotou Eleni is a Pulmonologist - Tuberculosis Specialist, holding a PhD from the Medical School of the National and Kapodistrian University of Athens and operates a private practice in Neo Faliro. Additionally, she holds a postgraduate degree in Thoracic Oncology from NKUA. She has extensive clinical experience, serves as a consultant at the private Metropolitan Hospital, and has previously collaborated with the Oncology Unit of the General Chest Diseases Hospital of Athens "Sotiria." Her expertise includes lung cancer, asthma, COPD - Chronic Obstructive Pulmonary Disease, and respiratory infections.

Nikolaou Aristeidis is a Pulmonologist with a private practice in Agios Dimitrios. He graduated from the Medical School of Aristotle University of Thessaloniki and in 2011 completed a postgraduate program at the National and Kapodistrian University of Athens focusing on International Medicine and Health Crisis Management. He has served as a scientific collaborator in the Oncology Department of the General Hospital for Chest Diseases of Athens "Sotiria" and has collaborated with the "Metropolitan" Hospital and the "Hygeia Melathron - TYPET," while currently working in the Medical Department of the pharmaceutical company "AstraZeneca." In his private practice, a patient-friendly environment that inspires trust and safety, he manages cases across the entire spectrum of Pulmonology, with particular expertise in the diagnosis, monitoring, and treatment of lung malignancies. Additionally, patients suffering from Chronic Obstructive Pulmonary Disease, bronchial asthma, and respiratory infections receive comprehensive information and evidence-based management and treatment regarding their condition. Finally, he is a member of the European Respiratory Society and the Hellenic Respiratory Society.

Marinos Stamatios is a Pulmonologist - Tuberculologist with a private practice in Glyfada (within the BIOCARE diagnostic center). He is a graduate of the Medical School and has completed postgraduate studies at the National and Kapodistrian University of Athens, specializing in Thoracic Oncology. After graduation and the completion of his mandatory rural service, he specialized in Internal Medicine at the General Hospital of Athens "Sismanoglio." Subsequently, he obtained the medical specialty title in Pulmonology - Tuberculosis from the General Hospital of Athens "Sismanoglio," acquiring extensive clinical experience in pulmonary diseases and tuberculosis. During his professional career, he served as a Registrar at the General Hospital of Athens "Sismanoglio," the General Hospital of Elefsina "Thriasio," and the General Hospital of Argolida. Additionally, he maintained private practices in Zurich, Switzerland, and in Kallithea, and continues to collaborate with public and private healthcare sectors. The doctor is a member of the Medical Association of Athens (ISA) and the Medical Association of Zurich and is committed to informing his patients through the articles he publishes. In his practice, in a friendly and warm environment, fully equipped, he offers a wide range of medical services in the field of Pulmonology and Tuberculology.

Glynos Konstantinos is Pulmonologist - Tuberculosis specialist in the private sector running his pulmonological office since 2015 in Nea Smyrne. He works as a medical advisor/manager and currently as Real-World Evidence (RWE) lead in GlaxoSmithKline (GSK). Since 2015, he has been working as medical advisor in the Respi department, for the Ellipta products (Relvar, Incruse, Anoro) and Nucala. Also he has been challenged in managing and couching MSL. His work has been recognized in GSK for the high accountability and teamwork in designing and executing customer centric solutions to overcome challenges and create new opportunities, especially in the era of Evidence Generation, conducting ISSs in Greece and designed, initiated and reviewed a GSK sponsored study titled “RElight” in collaboration with Greek the Hellenic Thoracic Society and also designed and initiated a European collaboration in evidence generation for patients with nasal polyps and asthma (“RESPONSE” and “MEPOLYP”). Previously, he has been working as a clinical consultant in the Intensive Care Unit of "Evangelismos" hospital, and as a post doc-research associate at the University Hospital of Ghent-Belgium and in the laboratory of Molecular Pharmacology of the University of Patras Pharmaceutical Division. His research work, focused on pathophysiology/molecular biology in obstructive airways disease (asthma and COPD), lung injury and sepsis, published in international peer-reviewed journals and awarded by the Greek and European Respiratory Society.

Ο Σαρρής Ευάγγελος είναι Ογκολόγος και διατηρεί ιατρείο στον Πειραιά. Είναι πτυχιούχος της Ιατρικής Σχολής Αθηνών και κάτοχος μεταπτυχιακού διπλώματος Ειδίκευσης στην Ογκολογία Θώρακος από την Ιατρική Σχολή του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών. Έλαβε την ειδικότητα της Παθολογικής Ογκολογίας το 2020, επιτυγχάνοντας εξαιρετική βαθμολογία (96/100) στις εξετάσεις για την απόκτηση του τίτλου ειδικότητας, ενώ το 2024 επιλέχθηκε να συμμετέχει στην ακαδημία του IASLC (International Association for the Study of Lung Cancer) ανάμεσα σε διακεκριμένους συναδέλφους με ειδίκευση στην Ογκολογία Θώρακος παγκοσμίως. Έχει πολυετή κλινική εμπειρία στην Ογκολογία, υπηρετώντας ως ειδικευόμενος και αργότερα ως επιμελητής σε αναγνωρισμένα νοσοκομεία της Αθήνας, ενώ εργάζεται ως Επιμελητής Παθολόγος - Ογκολόγος στην Δ' Ογκολογική Κλινική και Πρότυπο Κέντρο Κλινικών Μελετών του Metropolitan Hospital. Παράλληλα, είναι ενεργό μέλος σε ελληνικές και διεθνείς επιστημονικές εταιρείες (ESMO, IASLC, HeSMO, HeCOG) και συντονιστής του Ογκολογικού Συμβουλίου για τον Καρκίνο του Πνεύμονα στο Metropolitan Hospital. Διαθέτει σημαντικό ερευνητικό έργο, με πλούσια συγγραφική δραστηριότητα σε διεθνή επιστημονικά περιοδικά, ενώ έχει συμμετέχει ως ομιλητής σε πολυάριθμα Ελληνικά και διεθνή συνέδρια Ογκολογίας. Συμμετέχει ενεργά σε διεθνή προγράμματα, όπως το HORIZON 2020 – I3LUNG, καθώς και σε πολυάριθμες διεθνείς φάσεως ΙΙ και ΙΙΙ κλινικές μελέτες για τον καρκίνο του πνεύμονα, μεταξύ των οποίων η INTerpath-009, που αξιολογεί την αποτελεσματικότητα του mRNA εμβολίου V940 σε συνδυασμό με ανοσοθεραπεία σε ασθενείς με εξαιρέσιμο μη - μικροκυτταρικό καρκίνο του πνεύμονα μετά από εισαγωγική χημειοανοσοθεραπεία, και η μελέτη ARTEMIA, που συγκρίνει την αποτελεσματικότητα του πεπτιδικού εμβολίου OSE2101 έναντι της κλασικής χημειοθεραπείας σε ασθενείς με προχωρημένο μη - μικροκυτταρικό καρκίνο του πνεύμονα και δευτερογενή αντίσταση στην ανοσοθεραπεία. Η επιστημονική του προσέγγιση συνδυάζει την εξατομικευμένη ιατρική με τη σύγχρονη κλινική έρευνα, προσφέροντας στους ασθενείς του πρόσβαση σε καινοτόμες θεραπείες και υψηλού επιπέδου ογκολογική φροντίδα.

Oncologist Karagiannis Athanasios, at the Athens Bioclinic, is responsible for the complete design and administration of systemic (intravenous or oral) therapy such as classic chemotherapy and primarily immunotherapy and targeted molecular therapy, based on the results of molecular testing conducted on the tumor of each specific patient, aiming for individualized therapeutic selection in accordance with global guidelines, thus providing patients suffering from cancer access to the latest therapeutic options in immunotherapy and targeted therapy.

He also actively participates in the oncology board, through which decisions are made that determine the overall therapeutic approach to managing a malignant disease. This includes, besides systemic therapy, radiotherapy, surgical removal, and various local treatments (thermal ablation, embolization). The medical team of the oncology board includes physicians from all specialties involved in treating a malignant disease, such as surgical oncologists, radiation oncologists, interventional radiologists, internists, and pathologists, offering a comprehensive assessment of the disease, its treatment, and potential complications during the overall therapeutic course.

In our Oncology Department, numerous patients with lung cancer, stomach and intestinal cancer, pancreatic, liver, and biliary tract cancer, bladder and kidney cancer, and breast cancer are monitored.

Additionally, emphasis is placed on the complex therapeutic management of metastatic and advanced cancers through the simultaneous application of systemic and local therapies (directly to the metastatic site) in collaboration with the specialized interventional radiology department of the Athens Bioclinic.